Trevi Therapeutics Raises $150M to Advance Nalbuphine Program for Chronic Cough

Trevi Therapeutics announced the pricing of an underwritten public offering of 11.6 million shares at $13.00 per share, generating approximately $150 million in gross proceeds before underwriting fees and expenses. The clinical-stage biopharmaceutical company is leveraging the capital infusion to accelerate development of Haduvio (oral nalbuphine extended-release), its lead candidate targeting multiple chronic cough indications. The offering is expected to close on April 20, 2026, pending customary closing conditions and regulatory approvals.

This equity raise represents a significant financing milestone for the company as it pursues regulatory approval for a novel treatment addressing an underserved patient population with limited therapeutic options. The pricing reflects investor confidence in the company's clinical program, though the shares were offered below recent trading levels, suggesting market conditions required a modest discount to attract institutional capital.

Capital Deployment and Clinical Program

The $150 million in proceeds will support Trevi Therapeutics' ongoing clinical development efforts for Haduvio, which is designed as an oral extended-release formulation of nalbuphine, a mixed opioid agonist-antagonist with a favorable safety profile. The company is advancing the candidate across three distinct therapeutic areas:

• Idiopathic pulmonary fibrosis (IPF) with chronic cough
• Non-IPF interstitial lung disease (ILD) with chronic cough
• Refractory chronic cough in patients without underlying lung disease

This multi-indication approach provides Trevi with multiple pathways to commercial success and revenue diversification. Chronic cough remains a significant clinical challenge, particularly in IPF and ILD populations where limited therapeutic options exist beyond corticosteroids and antifibrotic agents. The burden of chronic cough in these patient populations substantially impacts quality of life, with persistent symptoms driving healthcare utilization and patient distress.

Nalbuphine's mechanism of action as a mixed opioid receptor modulator offers a pharmacologically differentiated approach compared to existing cough suppressants. The drug's partial agonist properties at mu receptors and antagonist activity at delta receptors are designed to provide antitussive efficacy while potentially minimizing risks associated with full opioid agonism, including respiratory depression—a critical safety consideration in lung disease populations.

Market Context and Competitive Landscape

The chronic cough therapeutics market remains fragmented and undersaturated, particularly for specialized indications like IPF-associated cough and refractory cough syndromes. Current standard-of-care options are limited, with most physicians relying on off-label use of opioid cough suppressants, antihistamines, and expectorants—none specifically developed or approved for these indications.

The IPF market has seen substantial growth following the approval of antifibrotic agents from companies including Boehringer Ingelheim and Genentech/Roche, which have transformed disease management. However, symptomatic management of IPF-associated complications, including chronic cough, remains a therapeutic gap. The global IPF diagnosis rate has expanded significantly in recent years due to improved awareness and diagnostic capabilities, creating a larger addressable patient population.

Recent market entries in the cough therapeutics space have demonstrated investor and clinical interest in novel approaches. The pricing of this offering at $13.00 per share reflects market valuation of Trevi's clinical assets relative to comparable clinical-stage biopharmaceutical companies developing respiratory and orphan disease therapeutics. The company's ability to raise capital at this valuation suggests investor belief in the clinical differentiation and commercial potential of Haduvio, though the discount to previous trading levels indicates equity dilution concerns and broader biotech sector volatility.

Investor Implications and Capital Structure

The 11.6 million share offering represents material dilution to existing shareholders, increasing outstanding share count and reducing proportional ownership percentages for current investors. However, the capital raised provides Trevi with substantial runway to advance clinical programs, fund regulatory submissions, and potentially initiate earlier-stage pipeline development activities.

For equity investors, the key metrics to monitor include:

• Clinical trial enrollment rates and topline efficacy data timelines for Phase 2/3 studies in each indication
• Regulatory pathway clarity, particularly FDA guidance on study design and approval pathways
• Cash burn rate and estimated runway relative to clinical milestones
• Share dilution impact on per-share economics and future financing needs
• Comparative efficacy versus existing therapies when clinical data emerges

The underwritten offering structure provides certainty around capital availability, eliminating dilution uncertainty that often plagues clinical-stage companies pursuing alternative financing mechanisms. This structured approach also signals management's commitment to a defined clinical development timeline with adequate resources.

Investors should recognize that Trevi Therapeutics operates in a sector characterized by binary clinical outcomes, regulatory uncertainty, and substantial execution risk. The chronic cough market, while underserved, remains relatively nascent from a commercial therapeutics perspective, requiring successful clinical validation before meaningful revenue materialization.

Forward-Looking Considerations

With $150 million in newly raised capital, Trevi Therapeutics is positioned to execute its clinical development strategy and potentially reach key inflection points including interim clinical data readouts and regulatory milestones. The timing of the offering, with closing expected in April 2026, suggests the company anticipated capital needs aligned with clinical development timelines.

The success of this equity raise demonstrates continued investor appetite for differentiated approaches to underserved therapeutic areas, even within the challenging biotech funding environment. However, investors should maintain disciplined approach to risk assessment, recognizing that clinical-stage development carries substantial execution risk and that commercial success of Haduvio remains contingent upon demonstrating clinical efficacy, safety, and tolerability in pivotal trials.

As Trevi Therapeutics advances Haduvio through clinical development, the company's ability to efficiently deploy capital, achieve clinical milestones, and maintain clear regulatory pathways will be essential determinants of long-term shareholder value creation.